Cybin Inc. (NYSE: CYBN) announced key highlights from its successful feasibility study conducted by its partner HI, LLC dba Kernel that tested its wearable technology to measure ketamine's psychedelic effect on the brain.

Results from this Cybin-sponsored study are intended to inform the future pathway for this program, explained CEO Doug Drysdale who called them “very promising. 

"The possibility of using this technology to develop a predictive tool to aid in identifying appropriate candidates for psychedelic-based therapy is also quite exciting, as is the convenience of a portable device, which could lend itself to more widespread use in clinical settings.”

Cybin's sponsorship in the feasibility study allows it to retain an exclusive interest in any innovations …

Full story available on Benzinga.com